A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Forman, Stephen J., M.D., F.A.C.P. Laboratory Bookmark and Share

Laboratory of Stephen J. Forman, M.D., F.A.C.P.

Advances in surgery, radiation therapy and chemotherapy over the last decade have increased the cure rates of a variety of malignancies. For patients whose tumors are not eradicated, however, the impediment most frequently encountered is the inability to fully eliminate the minimal residual disease that frequently has acquired resistance to conventional treatment modalities.
 
A conceptually attractive strategy for targeting minimal residual disease is the manipulation of immunologic effector cells to specifically recognize tumor targets. Animal models and an increasing number of clinical trials have implicated the T lymphocyte as a pivotal immunologic effector cell in antitumor immunity. Technologies are now available for identifying immunogenic T-cell target epitopes expressed by human tumors, isolating antigen-specific T-cell clones and expanding these clones ex vivo to large numbers for reinfusion. Initial clinical trials for malignant glioma employing adoptive transfer of glioma-specific cytolytic T lymphocytes have commenced at City of Hope.
 
Lab Members:
 
Research Group
Christine Brown, Ph.D.
Assistant Research Scientist
cbrown@coh.org
626-256-HOPE (4673),ext. 63977
 
Julie Ostberg, PhD.
Assistant Research Scientist
jostberg@coh.org
626-256-HOPE (4673),ext. 65249
 
Xiuli Wang, M.D., Ph.D.
Assistant Research Scientist
xiuwang@coh.org
626-256-HOPE (4673),ext. 63511
 
Wen Chung Chang, M.S.
Support Scientist
wchang@coh.org
626-256-HOPE (4673),ext. 64155
 
Brenda Aguilar, B.S.
Senior Research Associate
baguilar@coh.org
626-256-HOPE (4673),ext. 6392
 
Renate Starr, M.S.
Research Associate II
rstarr@coh.org
626-256-HOPE (4673),ext. 61135
 
Sean Cho, B.S.
Research Associate I
scho@coh.org
626-256-HOPE (4673),ext. 63048 
 
Hao Hong, Ph.D.
Research Fellow
hhong@coh.org
626-256-HOPE (4673),ext. 63927
 
Leonor Velasco
Research Lab Technician
lvelasco@coh.org
626-256-HOPE (4673),ext. 64181
 
T-cell Therapeutics and Research Lab
Araceli Hamlett, B.A.
Senior Research Associate
ahamlett@coh.org
626-256-HOPE (4673),ext. 64181
 
Jamie Wagner, B.A.
Senior Research Associate
jwagner@coh.org
626-256-HOPE (4673),ext. 64181
 
Winnie Wong, B.S.
Research Associate I
wiwong@coh.org
626-256-HOPE (4673),ext. 64181
 
Regulatory Affairs
Merle Alvarez
Consultant
mealvarez@coh.org
626-256-HOPE (4673),ext. 65684    
 
Graduate Students
Michelle Hunter, B.S.
Graduate Student
mhunter@coh.org
626-256-HOPE (4673),ext. 62153
 
Mahesh Jonnalagadda, DVM, MS
Graduate Student
mjonnalagadda@coh.org
626-256-HOPE (4673),ext. 64181
 
Megan Prosser, B.S.
Graduate Student
mprosser@coh.org
626-256-HOPE (4673),ext. 62153
 

Stephen J. Forman, M.D., F.A.C.P. Research

Adoptive Immunotherapy
Advances in surgery, radiation therapy and chemotherapy over the last decade have increased the cure rates of a variety of malignancies. For patients whose tumors are not eradicated, however, the impediment most frequently encountered is the inability to fully eliminate the minimal residual disease that often has acquired resistance to conventional treatment modalities. An attractive strategy for targeting minimal residual disease is the manipulation of immunologic effector cells to specifically recognize tumor targets. Animal models and an increasing number of clinical trials have implicated the T lymphocyte as a pivotal immunologic effector cell in anti-tumor immunity. This has led to our overall interest in using adoptive immunotherapy of T-cells to target cancer, specifically leukemia/lymphoma, brain tumors and neuroblastoma. Areas of focus in our research program are outlined below.
 
Glioma tumor cells are killed by therapeutic T-cells
Scanning of zetakine redirected cytolytic T-cell lysis of a glioma tumor cell.
 
Genetic Modification of T-cells for Redirected Tumor Recognition
Technologies are now available for identifying immunogenic T-cell target epitopes expressed by human tumors, isolating antigen-specific T-cells and expanding them ex vivo to large numbers for reinfusion. However, to overcome the difficulties of isolating tumor-reactive T-cells from cancer patients, we have developed technology to take T-cells from a cancer patient and reprogram them to target a patient’s cancer through genetic engineering strategies using DNA electroporation and/or lentiviral transduction. Previous studies by our laboratory have provided proof of principle that CTL can be engineered to specifically target lymphoma, neuroblastoma, and glioma tumors via expression of tumor-specific chimeric immunoreceptors resulting in MHC-independent killing of target tumor cells (Cooper et al, Blood 2003; Park et al, Mol Therapy 2007; Kahlon et al, Cancer Res 2004). More recently, we have completed pre-clinical studies of cytotoxic T-cells (CTLs) genetically modified to express an IL13-zetakine chimeric immunoreceptor to target cell-surface IL13Rα2 on medulloblastoma/primitive neuroectodermal tumors, the most common type of brain tumor in children (Stastny et al, J Ped Hematol Oncol 2007). Overall, we are currently involved in studying the potential clinical utility of adoptively transferring T-cells that have been genetically redirected to recognize CD19 (on leukemia and lymphoma); IL13Ra2 (on glioblastoma and medulloblastoma); L1-CAM (on neuroblastoma, lung cancer, and renal cell carcinoma); HER2 (on breast cancer, brain metastases and medulloblastoma); or alpha-3 integrin (on medulloblastoma).
 
 
Murine Xenograft ModelsSurgical suite
To monitor the therapeutic objectives of adoptive T-cell transfer before entering the clinical setting, our lab has developed multiple murine xenograft models. For example, we are now routinely performing stereotactic surgeries in mice for the intracranial injection of human brain tumors to mimic the situation of our patients. In addition, we have also developed lymphoma, neuroblastoma, and medulloblastoma murine xenograft models. Bioluminescent strategies have also been developed by our group for the in vivo imaging of both T-cells and tumors. Our utilization of the firefly and renilla luciferase genes (ffLuc and rLuc, respectively) along with the Xenogen system for serial imaging of anesthetized mice has been critically important for evaluating our animal studies. Specifically, these animal model systems are being used for studying the efficacy of immunotherapy, T-cell trafficking from tail vein injections, contralateral homing of T-cells to tumors within the parenchyma of the brain, and studies of T-cell persistence and proliferation.
 
Trafficking of Adoptively Transferred T-cells
To exert a therapeutic effect, adoptively transferred tumor-specific cytotoxic T-cells (CTLs) must traffic to sites of tumor burden, exit the circulation, and infiltrate the tumor microenvironment. T-cells are able to respond to migration directing chemicals, called chemokines, that are produced by tumor cells. Thus our group has begun to examine the ability of adoptively transferred human CTLs to traffic to tumors. Using a combination of in vivo tumor tropism studies, and in vitro biophotonic chemotaxis assays, we observed that tumors that produce CCL2/MCP1 (>10ng/ml), such as cell lines derived from glioma and medulloblastoma, efficiently chemoattract ex vivo expanded primary human T-cells. These studies suggest that the capacity of adoptively transferred T-cells to home to tumors may be influenced in part by the species and amounts of tumor-derived chemokines, in particular MCP-1 (Brown et al, J Immunol 2007).
 
Targeting Tumor Progenit or Cells with Genetically Engineered Effector T-Cells
Recent hypotheses that tumors arise from cancer stem cells which appear to be resistant to radiation treatment and chemotherapy have also led us to begin to isolate and expand stem cells from human glioma to assess the vulnerability of these cells to T-cell mediated killing in our adoptive immunotherapy models. Our initial studies demonstrate that chimeric immunoreceptor redirected IL13Rα2-specific CTL, currently being evaluated in an FDA-approved pilot Phase I trial for the treatment of recurrent/refractory malignant glioma, can kill cancer stem/progenitor cells in vitro, and reduce engrafted potential of the glioma stem/progenitor population in an orthotopic murine tumor model. Current models now predict that curative therapies for many cancers might require the elimination of the stem/progenitor population, and these studies lay the foundation for an immunotherapy approach to achieve this goal.
 
Development of Strategies to Optimize T-cell Anti-Tumor Activity in Vivo
Our group has also begun to investigate the expression of additional gene products in T-cells that may serve to overcome constraints on T-cell effector function and survival in vivo. For example, we are currently examining the efficacy of providing co-stimulatory signaling to T-cells through integration of costimulatory signaling domains within a tumor targeting chimeric antigen receptor.  Our recent studies in this area demonstrate that integrating costimulation with activation signaling events is important for fully activating CD4+ anti-tumor effector cells, resulting in sustained function in the tumor microenvironment.
 
Another strategy we are currently examining is the utility of genetically modifying T-cells which have first been selected for specificity to viruses such as CMV or EBV, which would allow for endogenous stimulation of these T-cells upon their transfer to patients infected with these viruses that are frequently reactivated in infected hosts. We would also predict that such a combinatorial bispecific T-cell strategy would permit the selective isolation of virus specific memory T-cells as recipients of chimeric antigen receptor genes for improved in vivo persistence following adoptive transfer. In fact, studies on the unique engraftment potential of memory T-cells are also being carried out in primates in collaboration with Dr. Berger at the Fred Hutchison Cancer Research Center in Seattle, WA. Because tumors can avoid immune-mediated elimination by production of immunosuppressive cytokines (e.g., TGF-b), our group is also evaluating strategies by which T-cells may be rendered resistant to such immunosupression. One project is the development of interference RNA sequences that could decrease this susceptibility of T-cells to tumor-mediated suppression. In collaboration with Sangamo Biosciences in Richmond, CA, we are also interested in studying the effects of genetically blocking glucocorticoid sensitivity of the tumor specific T-cells because post-operative brain cancer patients are routinely treated with immunosuppressive steroids (i.e., glucocorticoids) to reduce clinical symptoms of edema.
 
Lastly, another group of projects underway in the lab are examining ways of generating gene products that influence the expression of cytokines such as IL-2 and IL-7 which help promote the survival of T-cells and are critical for generating T-cell memory responses. A new collaboration with Dr. Smolke in the Chemical Engineering Department at CalTech involves the development of RNA regulating systems that are inducible by drugs such as tetracycline to control the expression of cytokines in T-cells which will promote their proliferation and survival.
 
Overall, the recent progress and current directions of Dr. Forman’s research group have generated much enthusiasm and support at City of Hope. The laboratory and office space in the Arnold and Mabel Beckman Center for Cancer Immunotherapeutics & Tumor Immunology is located in the heart of City of Hope. This state-of-the-art center is dedicated to immunotherapy and facilitates collaboration between lab researchers and clinicians, and rapidly moves scientific discoveries from the lab to patients.
 
 

Forman, Stephen J., M.D., F.A.C.P. Laboratory

Laboratory of Stephen J. Forman, M.D., F.A.C.P.

Advances in surgery, radiation therapy and chemotherapy over the last decade have increased the cure rates of a variety of malignancies. For patients whose tumors are not eradicated, however, the impediment most frequently encountered is the inability to fully eliminate the minimal residual disease that frequently has acquired resistance to conventional treatment modalities.
 
A conceptually attractive strategy for targeting minimal residual disease is the manipulation of immunologic effector cells to specifically recognize tumor targets. Animal models and an increasing number of clinical trials have implicated the T lymphocyte as a pivotal immunologic effector cell in antitumor immunity. Technologies are now available for identifying immunogenic T-cell target epitopes expressed by human tumors, isolating antigen-specific T-cell clones and expanding these clones ex vivo to large numbers for reinfusion. Initial clinical trials for malignant glioma employing adoptive transfer of glioma-specific cytolytic T lymphocytes have commenced at City of Hope.
 
Lab Members:
 
Research Group
Christine Brown, Ph.D.
Assistant Research Scientist
cbrown@coh.org
626-256-HOPE (4673),ext. 63977
 
Julie Ostberg, PhD.
Assistant Research Scientist
jostberg@coh.org
626-256-HOPE (4673),ext. 65249
 
Xiuli Wang, M.D., Ph.D.
Assistant Research Scientist
xiuwang@coh.org
626-256-HOPE (4673),ext. 63511
 
Wen Chung Chang, M.S.
Support Scientist
wchang@coh.org
626-256-HOPE (4673),ext. 64155
 
Brenda Aguilar, B.S.
Senior Research Associate
baguilar@coh.org
626-256-HOPE (4673),ext. 6392
 
Renate Starr, M.S.
Research Associate II
rstarr@coh.org
626-256-HOPE (4673),ext. 61135
 
Sean Cho, B.S.
Research Associate I
scho@coh.org
626-256-HOPE (4673),ext. 63048 
 
Hao Hong, Ph.D.
Research Fellow
hhong@coh.org
626-256-HOPE (4673),ext. 63927
 
Leonor Velasco
Research Lab Technician
lvelasco@coh.org
626-256-HOPE (4673),ext. 64181
 
T-cell Therapeutics and Research Lab
Araceli Hamlett, B.A.
Senior Research Associate
ahamlett@coh.org
626-256-HOPE (4673),ext. 64181
 
Jamie Wagner, B.A.
Senior Research Associate
jwagner@coh.org
626-256-HOPE (4673),ext. 64181
 
Winnie Wong, B.S.
Research Associate I
wiwong@coh.org
626-256-HOPE (4673),ext. 64181
 
Regulatory Affairs
Merle Alvarez
Consultant
mealvarez@coh.org
626-256-HOPE (4673),ext. 65684    
 
Graduate Students
Michelle Hunter, B.S.
Graduate Student
mhunter@coh.org
626-256-HOPE (4673),ext. 62153
 
Mahesh Jonnalagadda, DVM, MS
Graduate Student
mjonnalagadda@coh.org
626-256-HOPE (4673),ext. 64181
 
Megan Prosser, B.S.
Graduate Student
mprosser@coh.org
626-256-HOPE (4673),ext. 62153
 

Research

Stephen J. Forman, M.D., F.A.C.P. Research

Adoptive Immunotherapy
Advances in surgery, radiation therapy and chemotherapy over the last decade have increased the cure rates of a variety of malignancies. For patients whose tumors are not eradicated, however, the impediment most frequently encountered is the inability to fully eliminate the minimal residual disease that often has acquired resistance to conventional treatment modalities. An attractive strategy for targeting minimal residual disease is the manipulation of immunologic effector cells to specifically recognize tumor targets. Animal models and an increasing number of clinical trials have implicated the T lymphocyte as a pivotal immunologic effector cell in anti-tumor immunity. This has led to our overall interest in using adoptive immunotherapy of T-cells to target cancer, specifically leukemia/lymphoma, brain tumors and neuroblastoma. Areas of focus in our research program are outlined below.
 
Glioma tumor cells are killed by therapeutic T-cells
Scanning of zetakine redirected cytolytic T-cell lysis of a glioma tumor cell.
 
Genetic Modification of T-cells for Redirected Tumor Recognition
Technologies are now available for identifying immunogenic T-cell target epitopes expressed by human tumors, isolating antigen-specific T-cells and expanding them ex vivo to large numbers for reinfusion. However, to overcome the difficulties of isolating tumor-reactive T-cells from cancer patients, we have developed technology to take T-cells from a cancer patient and reprogram them to target a patient’s cancer through genetic engineering strategies using DNA electroporation and/or lentiviral transduction. Previous studies by our laboratory have provided proof of principle that CTL can be engineered to specifically target lymphoma, neuroblastoma, and glioma tumors via expression of tumor-specific chimeric immunoreceptors resulting in MHC-independent killing of target tumor cells (Cooper et al, Blood 2003; Park et al, Mol Therapy 2007; Kahlon et al, Cancer Res 2004). More recently, we have completed pre-clinical studies of cytotoxic T-cells (CTLs) genetically modified to express an IL13-zetakine chimeric immunoreceptor to target cell-surface IL13Rα2 on medulloblastoma/primitive neuroectodermal tumors, the most common type of brain tumor in children (Stastny et al, J Ped Hematol Oncol 2007). Overall, we are currently involved in studying the potential clinical utility of adoptively transferring T-cells that have been genetically redirected to recognize CD19 (on leukemia and lymphoma); IL13Ra2 (on glioblastoma and medulloblastoma); L1-CAM (on neuroblastoma, lung cancer, and renal cell carcinoma); HER2 (on breast cancer, brain metastases and medulloblastoma); or alpha-3 integrin (on medulloblastoma).
 
 
Murine Xenograft ModelsSurgical suite
To monitor the therapeutic objectives of adoptive T-cell transfer before entering the clinical setting, our lab has developed multiple murine xenograft models. For example, we are now routinely performing stereotactic surgeries in mice for the intracranial injection of human brain tumors to mimic the situation of our patients. In addition, we have also developed lymphoma, neuroblastoma, and medulloblastoma murine xenograft models. Bioluminescent strategies have also been developed by our group for the in vivo imaging of both T-cells and tumors. Our utilization of the firefly and renilla luciferase genes (ffLuc and rLuc, respectively) along with the Xenogen system for serial imaging of anesthetized mice has been critically important for evaluating our animal studies. Specifically, these animal model systems are being used for studying the efficacy of immunotherapy, T-cell trafficking from tail vein injections, contralateral homing of T-cells to tumors within the parenchyma of the brain, and studies of T-cell persistence and proliferation.
 
Trafficking of Adoptively Transferred T-cells
To exert a therapeutic effect, adoptively transferred tumor-specific cytotoxic T-cells (CTLs) must traffic to sites of tumor burden, exit the circulation, and infiltrate the tumor microenvironment. T-cells are able to respond to migration directing chemicals, called chemokines, that are produced by tumor cells. Thus our group has begun to examine the ability of adoptively transferred human CTLs to traffic to tumors. Using a combination of in vivo tumor tropism studies, and in vitro biophotonic chemotaxis assays, we observed that tumors that produce CCL2/MCP1 (>10ng/ml), such as cell lines derived from glioma and medulloblastoma, efficiently chemoattract ex vivo expanded primary human T-cells. These studies suggest that the capacity of adoptively transferred T-cells to home to tumors may be influenced in part by the species and amounts of tumor-derived chemokines, in particular MCP-1 (Brown et al, J Immunol 2007).
 
Targeting Tumor Progenit or Cells with Genetically Engineered Effector T-Cells
Recent hypotheses that tumors arise from cancer stem cells which appear to be resistant to radiation treatment and chemotherapy have also led us to begin to isolate and expand stem cells from human glioma to assess the vulnerability of these cells to T-cell mediated killing in our adoptive immunotherapy models. Our initial studies demonstrate that chimeric immunoreceptor redirected IL13Rα2-specific CTL, currently being evaluated in an FDA-approved pilot Phase I trial for the treatment of recurrent/refractory malignant glioma, can kill cancer stem/progenitor cells in vitro, and reduce engrafted potential of the glioma stem/progenitor population in an orthotopic murine tumor model. Current models now predict that curative therapies for many cancers might require the elimination of the stem/progenitor population, and these studies lay the foundation for an immunotherapy approach to achieve this goal.
 
Development of Strategies to Optimize T-cell Anti-Tumor Activity in Vivo
Our group has also begun to investigate the expression of additional gene products in T-cells that may serve to overcome constraints on T-cell effector function and survival in vivo. For example, we are currently examining the efficacy of providing co-stimulatory signaling to T-cells through integration of costimulatory signaling domains within a tumor targeting chimeric antigen receptor.  Our recent studies in this area demonstrate that integrating costimulation with activation signaling events is important for fully activating CD4+ anti-tumor effector cells, resulting in sustained function in the tumor microenvironment.
 
Another strategy we are currently examining is the utility of genetically modifying T-cells which have first been selected for specificity to viruses such as CMV or EBV, which would allow for endogenous stimulation of these T-cells upon their transfer to patients infected with these viruses that are frequently reactivated in infected hosts. We would also predict that such a combinatorial bispecific T-cell strategy would permit the selective isolation of virus specific memory T-cells as recipients of chimeric antigen receptor genes for improved in vivo persistence following adoptive transfer. In fact, studies on the unique engraftment potential of memory T-cells are also being carried out in primates in collaboration with Dr. Berger at the Fred Hutchison Cancer Research Center in Seattle, WA. Because tumors can avoid immune-mediated elimination by production of immunosuppressive cytokines (e.g., TGF-b), our group is also evaluating strategies by which T-cells may be rendered resistant to such immunosupression. One project is the development of interference RNA sequences that could decrease this susceptibility of T-cells to tumor-mediated suppression. In collaboration with Sangamo Biosciences in Richmond, CA, we are also interested in studying the effects of genetically blocking glucocorticoid sensitivity of the tumor specific T-cells because post-operative brain cancer patients are routinely treated with immunosuppressive steroids (i.e., glucocorticoids) to reduce clinical symptoms of edema.
 
Lastly, another group of projects underway in the lab are examining ways of generating gene products that influence the expression of cytokines such as IL-2 and IL-7 which help promote the survival of T-cells and are critical for generating T-cell memory responses. A new collaboration with Dr. Smolke in the Chemical Engineering Department at CalTech involves the development of RNA regulating systems that are inducible by drugs such as tetracycline to control the expression of cytokines in T-cells which will promote their proliferation and survival.
 
Overall, the recent progress and current directions of Dr. Forman’s research group have generated much enthusiasm and support at City of Hope. The laboratory and office space in the Arnold and Mabel Beckman Center for Cancer Immunotherapeutics & Tumor Immunology is located in the heart of City of Hope. This state-of-the-art center is dedicated to immunotherapy and facilitates collaboration between lab researchers and clinicians, and rapidly moves scientific discoveries from the lab to patients.
 
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
NEWS & UPDATES
  • Cancer research has yielded scientific breakthroughs that offer patients more options, more hope for survival and a higher quality of life than ever before. The 14.5 million cancer patients living in the United States are living proof that cancer research saves lives. Now, in addition to the clinic, hospital an...
  • Advances in cancer treatment, built on discoveries made in the laboratory then brought to the bedside, have phenomenally changed the reality of living with a cancer diagnosis. More than any other time in history, people diagnosed with cancer are more likely to survive and to enjoy a high quality of life. Howeve...
  • While health care reform has led to an increase in the number of people signing up for health insurance, many people remain uninsured or are not taking full advantage of the health benefits they now have. Still others are finding that, although their premiums are affordable, they aren’t able to see the do...
  • Kidney cancer rates and thyroid cancer rates in adults have continued to rise year after year. Now a new study has found that incidence rates for these cancers are also increasing in children — particularly in African-American children. The study, published online this month in Pediatrics, examined childhood ca...
  • Thyroid cancer has become one of the fastest-growing cancers in the United States for both men and women. The chance of being diagnosed with the cancer has nearly doubled since 1990. This year an estimated 63,000 people will be diagnosed with thyroid cancer in the United States and nearly 1,900 people will die ...
  • Older teenagers and young adults traditionally face worse outcomes than younger children when diagnosed with brain cancer and other central nervous system tumors. A first-of-its-kind study shows why. A team of researchers from the departments of Population Sciences and Pathology at City of Hope recently examine...
  • Cancer treatment can take a toll on the mouth, even if a patient’s cancer has nothing to do with the head or throat, leading to a dry mouth, or a very sore mouth, and making it difficult to swallow or eat. Here’s some advice from the National Cancer Institute (NCI)  on how to ease cancer-related dis...
  • Radiation oncology is one of the three main specialties involved in the successful treatment of cancer, along with surgical oncology and medical oncology. Experts in this field, known as radiation oncologists, advise patients as to whether radiation therapy will be useful for their cancer – and how it can best ...
  • There’s more to cancer care than simply helping patients survive. There’s more to cancer treatment than simple survival. Constant pain should not be part of conquering cancer,  insists Betty Ferrell, Ph.D., R.N., director of nursing research and education at City of Hope. She wants patients and caregivers...
  • Even its name is daunting. Systemic mastocytosis is a fatal disease of the blood with no known cure. But a new study suggests a bone marrow transplant may be the answer for some patients. While rare, systemic mastocytosis is resistant to treatment with drugs and, when aggressive, can be fatal within four years ...
  • Could what you eat affect the health of your chromosomes? The short answer is, “Yes.” Researchers led by Dustin Schones, Ph.D., assistant professor in the Department of Cancer Biology, and Rama Natarajan, Ph.D., director of the Division of Molecular Diabetes Research and the National Business Products Industry ...
  • September is Prostate Cancer Awareness Month. Here, Bertram Yuh, M.D., assistant clinical professor in the Division of Urology and Urologic Oncology at City of Hope, explains the importance of understanding the risk factors for the disease and ways to reduce those risks, as well as overall prostate health. “Wha...
  • ** Learn more about prostate health, plus prostate cancer research and treatment, at City of Hope. ** Learn more about getting a second opinion at City of Hope by visiting us online or by calling 800-826-HOPE (4673). City of Hope staff will explain what’s required for a consult at City of Hope and help yo...
  • Childhood cancer survival rates have increased dramatically over the past 40 years. More than 80 percent of children with cancer now survive five years or more, which is a tremendous feat. Despite the survival rate increase, cancer continues to be the No. 1 disease killer and second-leading cause of death in ch...
  • Although a stem cell transplant can be a lifesaving procedure for people diagnosed with a blood cancer or blood disorder, the standard transplant may not be appropriate for all patients. This is because the conditioning regimen (the intensive chemotherapy and/or radiation treatments preceding the transplant) is...